Literature DB >> 12687832

Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation.

Francesca Gensini1, Luigi Padeletti, Cinzia Fatini, Elena Sticchi, Gian Franco Gensini, Antonio Michelucci.   

Abstract

Experimental studies have shown a significant increase in angiotensin-converting enzyme (ACE) expression in atrial tissue of AF patients. ACE regulates the synthesis of endothelial nitric oxide (NO), which modulates autonomic nervous activity involved in the development of AF. The aim of the study was to evaluate the prevalence of ACE insertion/deletion and endothelial NO synthase (eNOS) T-786C, G894T, and 4a/4b polymorphisms in 148 patients with persistent AF, compared with 210 control subjects. ACE insertion/deletion polymorphism genotype distribution and allele frequency were significantly different between patients and controls (P < 0.0001 and P < 0.0001, respectively). ACE DD genotype was significantly associated with the risk of AF (OR DD/ID + II = 3.24, P < 0.0001). Analysis of eNOS polymorphisms showed no significant difference in genotype distribution and allele frequency between patients and controls. The results suggest a possible role of ACE DD genotype as a predisposing factor to AF and a pathophysiological mechanism of ACE inhibition in reducing the incidence of AF in patients with left ventricular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12687832     DOI: 10.1046/j.1460-9592.2003.00036.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  15 in total

Review 1.  Association between endothelial nitric oxide synthase polymorphisms and atrial fibrillation: a meta-analysis.

Authors:  Hongying Chen; Hongxia Chu; Yu Shi; Soumitra Sudip Bhuyan; Jian ping Li; Shao Rong Liu; Jun Yang
Journal:  J Cardiovasc Transl Res       Date:  2012-06-22       Impact factor: 4.132

Review 2.  [New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers].

Authors:  M Hammwöhner; A D'Alessandro; D Dobrev; P Kirchhof; A Goette
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

3.  Lack of replication in polymorphisms reported to be associated with atrial fibrillation.

Authors:  Moritz F Sinner; Steven A Lubitz; Arne Pfeufer; Seiko Makino; Britt-Maria Beckmann; Kathryn L Lunetta; Gerhard Steinbeck; Siegfried Perz; Rosanna Rahman; Akshata Sonni; Steven M Greenberg; Karen L Furie; H-Erich Wichmann; Thomas Meitinger; Annette Peters; Emelia J Benjamin; Jonathan Rosand; Patrick T Ellinor; Stefan Kääb
Journal:  Heart Rhythm       Date:  2010-11-04       Impact factor: 6.343

Review 4.  [Genetics of atrial fibrillation: rare mutations, common variants and clinical relevance?].

Authors:  M F Sinner; A Pfeufer; S Kääb
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

5.  A common angiotensin-converting enzyme polymorphism and preoperative angiotensin-converting enzyme inhibition modify risk of tachyarrhythmias after congenital heart surgery.

Authors:  Andrew H Smith; English C Flack; Kristie Y Borgman; Jill P Owen; Frank A Fish; David P Bichell; Prince J Kannankeril
Journal:  Heart Rhythm       Date:  2014-01-01       Impact factor: 6.343

Review 6.  Neurohormonal intervention to reduce sudden cardiac death in heart failure: what is the optimal pharmacologic strategy?

Authors:  Iain Squire
Journal:  Heart Fail Rev       Date:  2004-10       Impact factor: 4.214

7.  The 894G Allele of the Endothelial Nitric Oxide Synthase 3 (eNOS) is Associated with Atrial Fibrillation in Chronic Systolic Heart Failure.

Authors:  Fuad Fares; Yoav Smith; Naiel Azzam; Barak Zafrir; Basil S Lewis; Offer Amir
Journal:  J Atr Fibrillation       Date:  2012-12-16

Review 8.  Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation.

Authors:  Kristian Wachtell; Richard B Devereux; Paulette A Lyle
Journal:  Curr Cardiol Rep       Date:  2006-09       Impact factor: 2.931

Review 9.  The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS.

Authors:  Giuseppina Novo; Daniela Guttilla; Giovanni Fazio; Debbie Cooper; Salvatore Novo
Journal:  Br J Clin Pharmacol       Date:  2008-09       Impact factor: 4.335

10.  ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling.

Authors:  Hiroshi Watanabe; Daniel W Kaiser; Seiko Makino; Calum A MacRae; Patrick T Ellinor; Brian S Wasserman; Prince J Kannankeril; Brian S Donahue; Dan M Roden; Dawood Darbar
Journal:  Heart Rhythm       Date:  2009-05-15       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.